UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline ...
PARIS, FRANCE, 22 October 2026 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the year-to-date and third quarter of 2026.
New Recommendations for JAK Inhibitors, Anemia and Transplantation / American Society of Hematology (ASH), ASH 2026 ...
The American Society of Hematology (ASH) released guidelines on the management of myelofibrosis, a rare and life-threatening blood cancer. ASH's new ...
The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...
Syndax Pharmaceuticals (NASDAQ:SNDX) shares fell 15% after-hours Monday following the company’s announcement that its axatilimab drug failed to meet the primary endpoint in a Phase 2 trial for ...
—With the help of routine blood tests focused on white blood cell and platelet levels, an international team of researchers set out to create a clinically applicable model to distinguish prefibrotic ...
Primary myelofibrosis (PMF) is a BCR/ABL1-negative myeloproliferative neoplasm (MPN) with a shorter overall survival and a higher leukemic transformation than other BCR/ABL1-negative MPNs. Diagnosis ...
Primary hypertrophic osteoarthropathy (PHO) is a rare hereditary clinical syndrome characterized by digital clubbing, periostosis, and pachydermia. It is mainly caused by mutations in SLCO2A1 or HPGD, ...
The hazard ratio that will dominate conversations at EHA 2026 is 0.43: a more than 50 percent reduction in the risk of death observed in the combination arm of the phase 3 SENTRY trial, comparing ...
3. Purpose: Treatment of Pre-fibrotic/Early Primary Myelofibrosis or Overt Primary Myelofibrosis at low or intermediate-1 risk according to DIPSS Plus. 4. All development stages expected to be ...
Missing one of its co-primary endpoints could make it difficult for Karyopharm Therapeutics to score conventional approval for Xpovio in myelofibrosis, according to Jefferies analysts. Karyopharm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results